钠-葡萄糖协同转运蛋白2抑制剂在腹膜透析中的研究及应用前景  

Sodium-glucose co-transporter 2 inhibitors in peritoneal dialysis patients

作　　者：余乐 成水芹(综述) 俞雨生(审校) YU Le;CHENG Shuiqin;YU Yusheng(National Clinical Research Center for Kidney Diseases,Jinling Hospital,Nanjing 210016,China)

机构地区：[1]东部战区总医院国家肾脏疾病临床医学研究中心,南京210016

出　　处：《肾脏病与透析肾移植杂志》2024年第4期372-376,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：国家自然科学基金面上项目(82370733)。

摘　　要：钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一种新型口服降糖药,对2型糖尿病或非糖尿病患者都表现出良好的心肾保护作用,并可改善慢性肾脏病患者的心肾结局。虽然目前临床试验已将纳入人群的估算肾小球滤过率(eGFR)扩展至更低水平,但仍排除了eGFR<20 mL/(min·1.73 m 2)的患者,SGLT2i的心肾保护作用能否延续至维持性透析期是临床关注的重点。此外,SGLT2i的抗炎和抗纤维化作用可能对腹膜透析(PD)患者维持腹膜功能有益。因此,SGLT2i在PD患者中的应用值得进一步探索。Sodium-glucose co-transporter 2 inhibitors(SGLT2i),a novel type of oral antihyperglycaemic drugs,have demonstrated favorable cardiorenal protective effects in patients with type 2 diabetes or non-diabetic individuals.They can also improve cardiorenal outcomes in patients with chronic kidney disease.Although clinical trials have expanded the inclusion criteria for estimated glomerular filtration rate(eGFR)to lower levels,patients with eGFR<20 ml/min/1.73m^2 are still excluded.Whether the continuation of cardiorenal protective effects of SGLT2i during the maintenance dialysis phase is an area of clinical focus.Additionally,the anti-inflammatory and anti-fibrotic properties of SGLT2i may benefit the preservation of peritoneal function in patients undergoing peritoneal dialysis(PD).Therefore,further exploration of the application of SGLT2i in PD patients is warranted.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 腹膜透析 心肾保护 残余肾功能 腹膜 

分 类 号：R692.5[医药卫生—泌尿科学]